New combo therapy targets rare bile duct cancer gene
Disease control
Recruiting now
This study tests whether combining two drugs (pemigatinib and durvalumab) can shrink or control advanced bile duct cancer that has a specific FGFR2 gene change. About 38 adults whose cancer has not responded to prior treatment will receive daily pills and an IV infusion every 3 w…
Phase: PHASE2 • Sponsor: Mehmet Akce • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC